CanSense
Swansea
About CanSense
CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.1M
- Funding stage: Seed
- Last round: Seed (Mar 2023)
- Website: cansenseltd.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/cansense-5207 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.